Fiche publication
Date publication
décembre 2020
Journal
Current drug targets
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Loy L, Fiorino G, Roda G, Allocca M, Furfaro F, Zilli A, Gilardi D, Radice S, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
The increasing armamentarium of drugs for inflammatory bowel disease (IBD) requires a direct comparison of different therapeutic options in order to guide physicians in the choice of the most appropriate treatment for their patients. Head-to-head trials, considered the gold standard in comparative research in IBD, allow to compare different therapies in the same population and setting, but also to evaluate different treatment strategies. Despite head-to-head trials including biologics and immunosuppressive therapy in IBD have been performed decades ago, the interest of these direct comparison is growing since the publication of the first randomized controlled trial directly comparing biologic agents with different molecular targets. This review provides an overview of the past and current IBD head-to-head trial, considering their respective strengths and limitations in a real-life setting.
Mots clés
Inflammatory bowel disease, direct comparison, head-to-head trial, randomized clinical trial, treatment strategy
Référence
Curr Drug Targets. 2020 Dec 11;:
